Dianthus Therapeutics DNTH Free cash flow yield
Free cash flow yield at other companies
Other financials
Where this comes from
Calculated from Dianthus Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: Dianthus Therapeutics’s 10-Q, filed November 5, 2025, on SEC EDGAR. View the filing →
Ask your AI about Dianthus Therapeutics's free cash flow yield.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Dianthus Therapeutics's free cash flow yield?
- Dianthus Therapeutics (DNTH) reported free cash flow yield of -7% in Q3 2025.
- How has Dianthus Therapeutics's free cash flow yield changed year-over-year?
- Dianthus Therapeutics's free cash flow yield decreased by 4.7% year-over-year, from -6.7% to -7%.
- What is the long-term trend for Dianthus Therapeutics's free cash flow yield?
- Over 3 years (2020 to 2024), Dianthus Therapeutics's free cash flow yield has grown at a -10.5% compound annual growth rate (CAGR), from -16.9% to -12.1%.
- What does free cash flow yield mean?
- Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.